Tesamorelin and Sermorelin – Key Differences

Tesamorelin and sermorelin are peptides that stimulate the natural production of growth hormone (GH), but they are used for slightly different purposes and have varying levels of clinical evidence [1–4]. Tesamorelin is generally considered more potent and better studied for reducing visceral fat and improving metabolic health, while sermorelin is more frequently associated with general growth hormone support, healthy aging, regeneration, and hormonal optimization [1–4].

Tesamorelin was approved by the FDA for the reduction of excess visceral fat in people with HIV-related lipodystrophy, while sermorelin was originally used for the diagnosis and treatment of growth hormone deficiency in children and later began to be used off-label in wellness and hormone optimization therapies in adults [1,5].

Both peptides work through a similar hormonal pathway. They bind to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland, stimulating the body to secrete its own GH [2,6]. The resulting increase in GH then boosts the production of insulin-like growth factor-1 (IGF-1), which influences fat metabolism, tissue repair, maintenance of muscle mass, recovery, and energy regulation [2,6].

However, there are significant structural differences between these peptides. Tesamorelin is a stabilized synthetic version of human GHRH consisting of 44 amino acids and contains a special trans-3-hexenoic acid modification that improves stability and prolongs activity in the body [1,7]. Sermorelin, on the other hand, contains only the first 29 amino acids of natural GHRH and is considered a classic GHRH analog [6].

Tesamorelin has significantly stronger clinical evidence regarding the reduction of visceral fat, abdominal fat, and fatty liver disease. In large Phase III trials, Falutz et al. (2010) demonstrated that tesamorelin reduced visceral fat by approximately 15.4% over 26 weeks, while improving triglyceride levels and cholesterol ratios without significantly impairing glycemic control [8]. Long-term studies have shown that these effects could be maintained for up to 52 weeks of continuous therapy [9].

Further research by Stanley et al. (2014) showed that tesamorelin significantly reduced both visceral fat and hepatic fat in individuals with HIV and excessive abdominal fat accumulation [10]. Subsequent studies on HIV-associated NAFLD demonstrated a relative reduction in hepatic fat of approximately 37% after 12 months of therapy [11].

Research on sermorelin focuses more on restoring natural GH production and supporting healthy aging rather than directly impacting visceral fat. Corpas et al. (1992) demonstrated that sermorelin increased GH and IGF-1 levels in older individuals to values closer to those observed in younger individuals [3]. Khorram et al. (1997), on the other hand, found that long-term sermorelin therapy improved lean body mass, skin thickness, insulin sensitivity, libido, and general well-being in older men and women [4]. Vittone et al. (1997) also showed that nocturnal sermorelin injections increased natural nocturnal GH secretion without causing excessively high hormone levels [12].

Another significant difference is the intensity of hormonal action. Tesamorelin usually causes a stronger increase in IGF-1 and more pronounced changes in visceral fat and metabolic markers [8–11]. Sermorelin, on the other hand, is considered milder and more physiological, meaning it may more gently mimic natural GH signaling originating from the hypothalamus. For this reason, sermorelin is often chosen in healthy aging or hormonal optimization programs focused on long-term body support, sleep quality, regeneration, and gradual support of natural GH production, rather than aggressive fat reduction or metabolic therapy [3,4,12].

Both peptides are generally considered safer than direct recombinant human growth hormone (HGH) therapy as they stimulate the body to produce its own GH rather than supplying the hormone from external sources. The most commonly reported side effects in tesamorelin studies include:

• Injection site reactions
• mild water retention and swelling
• joint pain (arthralgia)
• occasional problems with glucose control [8,9]

The side effects of sermorelin are usually mild and may include:

• skin redness
• headaches
• nausea
• dizziness
• injection site irritation [4,6]

Since both peptides increase GH and IGF-1 activity, monitoring metabolic and hormonal parameters remains important, especially in individuals at risk of diabetes, with endocrine disorders, or a history of cancer.

In practice, tesamorelin is usually a better-documented option when the goal is evidence-based reduction of visceral fat, improvement of fatty liver, and support of metabolic health, especially in individuals with central obesity or HIV-associated lipodystrophy [8–11]. Sermorelin is more often used in the context of general hormonal optimization, healthy aging, regeneration, sleep quality, and gradual support of natural GH production [3,4,12].

Generally speaking, the better choice depends on the main goal of the therapy. Tesamorelin is stronger in terms of its impact on metabolism and body composition, while sermorelin is often perceived as a milder option for long-term GH support and wellness-oriented hormone optimization.

From the perspective of the research peptides market, peptides such as tesamorelin and sermorelin are also available from suppliers like Semax Polska exclusively for laboratory and scientific research.

Disclaimer

This content is for educational and informational purposes only and does not constitute medical, diagnostic, or therapeutic advice. Tesamorelin and sermorelin affect the growth hormone and IGF-1 axis and should only be used under the supervision of a qualified specialist with appropriate laboratory monitoring. Individual physiological responses, risks, and legal status may vary depending on medical history and country. Research-use-only peptides offered by suppliers such as Semax Polska are intended solely for laboratory and scientific research.

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
2. Pombo, C. M., Zalvide, J., Gaylinn, B. D., et al. (2000). Growth hormone-releasing hormone stimulates mitogen-activated protein kinase. Endocrinology, 141(6), 2113–2119. https://doi.org/10.1210/endo.141.6.7513
3. Corpas, E., Harman, S. M., Piñeyro, M. A., Roberson, R., & Blackman, M. R. (1992). Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. The Journal of Clinical Endocrinology & Metabolism, 75(2), 530–535. https://doi.org/10.1210/jcem.75.2.1379256
4. Khorram, O., Laughlin, G. A., & Yen, S. S. C. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of Clinical Endocrinology & Metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943
5. Prakash, A., & Goa, K. L. (1999). Sermorelin: A review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2), 139–157. https://doi.org/10.2165/00063030-199912020-00007
6. Bowers, C. Y. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316–1329. https://doi.org/10.1007/s000180050257
7. PubChem. (2025). Tesamorelin Compound Summary. National Center for Biotechnology Information, National Library of Medicine.
8. Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
9. Falutz, J., Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
10. Stanley, T. L., Feldpausch, M. N., Oh, J., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
11. Stanley, T. L., Fourman, L. T., Feldpausch, M. N., et al. (2019). Effect of tesamorelin on nonalcoholic fatty liver disease in HIV-positive individuals: A randomized, double-blind, multicenter study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
12. Vittone, J., Blackman, M. R., Busby-Whitehead, J., et al. (1997). Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism, 46(1), 89–96. https://doi.org/10.1016/S0026-0495(97)90174-8